| 1. |
Benzie, I. F. F. (2000) Evolution of antioxidant defence mechanisms. Eur. J. Nutr.
39, 53–61.
|
| |
| 2. |
Maxwell, S R. J. and Lip, G Y. H. (1997) Reperfusion injury: A review of the pathophysiology, clinical manifestations and
therapeutic options. Int. J. Cardiol.
58, 95–117.
|
| |
| 3. |
Bourdon, E. and Blache, D. (2001) The importance of proteins in defense against oxidation. Antiox. Redox Sign.
3, 293–311.
|
| |
| 4. |
Bolli, R. (1998) Causative role of oxyradicals in myocardial stunning: A proven hypothesis. Basic. Res. Cardiol.
93, 156–162.
|
| |
| 5. |
Das, D K., Engelman, R M., Liu, X., Maity, S., Rousou, J. A., Flack, J., et al. (1992) Oxygen-derived free radicals and hemolysis
during open heart surgery. Mol. Cell. Biochem.
111, 77–86.
|
| |
| 6. |
Singal, P K, Khaper, N., Palace, V., and Kumar, D. (1998) The role of oxidative stress in the genesis of heart disease. Cardiovasc. Res.
40, 426–432.
|
| |
| 7. |
Hejjel, L. and Roth, E. (2000) Molecular, cellular, and clinical aspects of myocardial ischemia. Orv. Hetil.
141, 539–546.
|
| |
| 8. |
Toufektsian, M C., Boucher F R., Morel, T S., and De Leiris, J G. (2001) Cardiac toxicity of singlet oxygen: Implication in
reperfusion injury. Antiox. Redox Sign.
3, 63–69.
|
| |
| 9. |
Das, D K. (2001) Redox regulation of cardiomyocyte survival and death. Antiox. Redox Sign.
3, 23–37.
|
| |
| 10. |
Griendling, K K. and Ushio-Fukai, M. (2000) Reactive oxygen species as mediators of angiotensin II signaling. Regul. Pept.
91, 21–27.
|
| |
| 11. |
Irani, K. (2000) Oxidant signaling in vascular cell growth, death, and survival. Circ. Res.
87, 179–183.
|
| |
| 12. |
Webster, K A., Prentice, H., and Bishopric, N H. (2001) Oxidation of zinc finger transcription factors: Physiological consequences.
Antiox. Redox Sign.
3, 535–548.
|
| |
| 13. |
Okabe, E., Tsujimoto, Y., and Kobayashi, Y. (2000) Calmodulin and cyclic ADP-ribose interaction in Ca signaling related to
cardiac sarcoplasmic reticulum: Superoxide anion radical-triggered Ca-release. Antiox. Redox Signal.
2, 47–54.
|
| |
| 14. |
Goldhaber, J I. and Qayyum, M S. (2000) Oxygen free radicals and excitation-contraction coupling. Antiox. Redox Signal.
2, 55–64.
|
| |
| 15. |
Agrawal, A. and Kale, R K. (2001) Radiation induced peroxidative damage: Mechanism and significance. Indian J. Exp. Biol.
39, 291–309.
|
| |
| 16. |
Entman, M L. and Smith, C W. (1994) Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease.
Cardiovasc. Res.
28, 1301–1311.
|
| |
| 17. |
Griendling, K K., Sorescu, D., and Ushio-Fukai, M. (2000) NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ. Res.
86, 494–501.
|
| |
| 18. |
Cai, H. and Harrison, D G. (2000) Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ. Res.
87, 840–844.
|
| |
| 19. |
Trochu, J.-N., Bouhour, J.-B., Kaley, G., and Hintze, T H. (2000) Role of endothelium-derived nitric oxide in the regulation
of cardiac oxygen metabolism. Circ. Res.
87, 1108–1117.
|
| |
| 20. |
Dhalla, N. S., Elmoselhi, A B., Hata, T., and Makino, N. (2000) Status of myocardial antioxidants in ischemia-reperfusion
injury. Cardiovasc. Res.
47, 446–456.
|
| |
| 21. |
Engelhardt, J. F., Sen, C K., and Oberley, L. (2001) Redox-modulating gene therapies for human diseases. Antiox. Redox Sign.
3, 341–346.
|
| |
| 22. |
Guidot, D. M., Repine, J. E., Kitlowski, A. D., Flores, S. C., Nelson, S. K., Wright, R. M., et al. (1995) Mitochondrial respiration
scavenges extramitochondrial superoxide via non-enzymatic mechanism. Clin. Invest.
96, 1131–1136.
|
| |
| 23. |
Wang, X. L., Adachi, T., Sim, A. S., and Wilcken, D. E. (1998) Plasma extracellular superoxide dismutase levels in an Australian
population with coronary artery disease. Arterioscler. Thromb. Vasc. Biol.
18, 1915–1921.
|
| |
| 24. |
Benjamin, I. J. and McMillan, D. R. (1998) Stress (heat shock) proteins. Molecular chaperones in cardiovascular biology and
disease. Circ. Res.
83, 117–132.
|
| |
| 25. |
Das, U. N. (2000) Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol. Cell. Biochem.
215, 145–152.
|
| |
| 26. |
Chen, W., Gabel, S., Steenberger, C., and Murphy, E. (1995) A redox-based mechanism for cardioprotection induced by ischemic
preconditioning in perfused rat heart. Circ. Res.
77, 424–429.
|
| |
| 27. |
Cohen, M. V., Yang, X-M., Liu, G. S., Heusch, G., and Downey, J. M. (2001) Acetylcholine, bradykinin, opioids, and phenylephrine,
but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial KATP channels. Circ. Res.
89, 273–278.
|
| |
| 28. |
Tanaka, M., Fujiwara, H., Yamasaki, K., and Sasayama, S. (1994) Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate
infarct size limitation effect of ischemic preconditioning in the rabbit. Cardiovasc. Res.
28, 980–986.
|
| |
| 29. |
Yamashita, N., Hoshida, S., Taniguchi, N., Kuzuya, T., and Hori, M. (1998) Whole-body hyperthermia provides biphasic cardioprotection
against ischemia/reperfusion injury in the rat. Circulation
98, 1414–1421.
|
| |
| 30. |
Tritto, I. and Ambrosio, G. (2001) Role of oxidants in the signaling pathway of preconditioning. Antiox. Redox Sign.
3, 3–10.
|
| |
| 31. |
Siwik, D. A., Pagano, P. J., and Colucci, W. S. (2001) Oxidative stress regulates collagen synthesis and matrix metalloproteinase
activity in cardiac fibroblasts. Am. J. Physiol.
280, C53–C60.
|
| |
| 32. |
Szibor, M., Richter, C., and Ghafourifar, P. (2001) Redox control of mitochondrial functions. Antiox. Redox Sign.
3, 515–523.
|
| |
| 33. |
Semenza, G. L. (2000) Cellular and molecular dissection of reperfusion injury. ROS within and without. Circ. Res.
86, 117–118.
|
| |
| 34. |
Rakhit, R. D. and Marber, M. S. (2001) Nitric oxide: An emerging role in cardioprotection? Heart
86, 368–372.
|
| |
| 35. |
Wink, D. A., Miranda, K. M., Espey, M. G., Pluta, R. M., Hewett, S. J., Colton, C., et al. (2001) Mechanism of the antioxidant
effects of nitric oxide. Antiox. Redox Sign.
3, 203–213.
|
| |
| 36. |
Cooke, J. P. (1998) Nutriceuticals for cardiovascular health. Am. J. Cardiol.
82, 43S–46S.
|
| |
| 37. |
Guigliano, D. (2000) Dietary antioxidants for cardiovascular prevention. Nutr. Metab. Cardiovasc. Dis.
10, 38–44.
|
| |
| 38. |
Pryor, W. (2000) Vitamin E and heart disease: Basic science to clinical intervention trials. Free Rad. Biol. Med.
28, 141–164.
|
| |
| 39. |
Sethi, R., Takeda, N., Nagano, M., and Dhalla, N. S. (2000) Beneficial effects of vitamin E treatment in acute myocardial
infarction. J. Cardiovasc. Pharmacol. Ther.
5, 51–58.
|
| |
| 40. |
Kritchevsky, S. B., Shimakawa, T., Tell, G. S., et al. (1995) carotid artery wall thickness. The ARIC Study. Atherosclerosis
Risk in Communities Study. Circulation
92, 2142–2150.
|
| |
| 41. |
Hodis, H. N., Mack, W J., LaBree, L., et al. (1995) Serial coronary angiographic evidence that antioxidant vitamin intake
reduces progression of coronary artery atherosclerosis. JAMA
273, 1849–1854.
|
| |
| 42. |
Stephens, N. G., Parsons, A., Schofield, P. M., Kelly, F., Cheeseman, K., and Mitchinson, M. J. (1996) Randomised controlled
trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet
347, 781–786.
|
| |
| 43. |
GISSI (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results
of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet
354, 447–455.
|
| |
| 44. |
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E., Colditz, G. A., and Willett, W. C. (1993) Vitamin E consumption
and the risk of coronary heart disease in men. N. Engl. J. Med.
328, 1450–1456.
|
| |
| 45. |
Stampfer, M. J., Hennekens, C. H., Manson, J. E., Colditz, G. A., Rosner, B., and Willett, W. C. (1993) Vitamin E consumption
and the risk of coronary disease in women. N. Engl. J. Med.
328, 1444–1449.
|
| |
| 46. |
Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., and Sleight, P. (2000) Vitamin E supplementation and cardiovascular events
in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med
342, 154–160.
|
| |
| 47. |
Lonn, E., Yusuf, S., Dzavik, V., Doris, C., Yi, Q., Smith, S., et al., for the SECURE Investigators. (2001) Effects of ramipril
and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin
E (SECURE). Circulation
103, 919–925.
|
| |
| 48. |
Solzbach, U., Hornig, B., Jeserich, M., and Just, H. (1997) Vitamin C improves endothelial dysfunction of epicardial coronary
arteries in hypertensive patients. Circulation
96, 1513–1519.
|
| |
| 49. |
Hornig, B., Arakawa, N., Kohler, C., and Drexler, H. (1998) Vitamin C improves endothelial function of conduit arteries in
patients with chronic heart failure. Circulation
97, 363–368.
|
| |
| 50. |
Yokoyama, H., Lingle, D. M., Crestanello, J. A., Kamelgard, J., Kott, B. R., Momeni, R., et al. (1996) Coenzyme Q10 protects
coronary endothelial function from ischemia reperfusion injury via an antioxidant effect. Surgery
120, 189–196.
|
| |
| 51. |
Tran, M. T., Mitchell, T. M., Kennedy, D. T., and Giles, J. T. (2001) Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy
21, 797–806.
|
| |
| 52. |
Miller, A. L. (1996) Antioxidant flavonoids: Structure, function and clinical usage. Alt. Med. Rev.
1, 103–111.
|
| |
| 53. |
Hultzquist, D. E., Xu, F., Quandt, K. S., Shlafer, M., Mack, C. P., Till, G. O., et al. (1993) Evidence that NADPH-dependent
methemoglobin reductase and administered riboflavin protect tissues from oxidative injury. Am. J. Hematol.
42, 13–18.
|
| |
| 54. |
Herrog, M. G. L., Feskens, E. J. M., Hollman, P. C. H., Katman, M. B., and Krombout, D. (1993) Dietary antioxidant flavonoids
and risk of coronary heart disease: The Zutphen elderly study. Lancet
342, 1007–1011.
|
| |
| 55. |
Knekt, P., Reunanen, A., Järvinen, R., Seppänen, R., Heliövaara, M., and Aromaa, A. (1994) Antioxidant vitamin intake and
coronary mortality in a longitudinal population study. Am. J. Eepidemiol.
139, 1180–1189.
|
| |
| 56. |
Rimm, E. B., Katan, M. B., Ascherio, A., Stampfer, M. J., and Willett, W. C. (1996) Relation between intake of flavonoids
and risk for coronary heart disease in male health professionals. Ann. Intern. Med.
125, 384–389.
|
| |
| 57. |
Lin, J. K. and Tsai, S. H. (1999) Chemoprevention of cancer and cardiovascular disease by resveratrol. Proc. Natl. Sci. Counc. Repub. China B
203, 99–106.
|
| |
| 58. |
Dobsak, P., Courderot-Masuyer, C., Zeller, M., Vergely, C., Laubriet, A., Assem, M., et al. (1999) Antioxidative properties
of pyruvate and protection of the ischemic rat heart during cardioplegia. J. Cardiovasc. Pharmacol.
34, 651–659.
|
| |
| 59. |
Chahine, R. and Feng, J. (1998) Protective effects of Taurine against reperfusion-induced arrhythmias in isolated ischemic
rat heart. Arzneimittelforschung
48, 360–364.
|
| |
| 60. |
Reiter, R. J., Tan, D. X., Qi, W., Manchester, L. C., Karbownik, M., and Calvo, J. R. (2000) Pharmacology and physiology of
melatonin in the reduction of the oxidative stress in vivo. Biol. Signals Recept.
9, 160–171.
|
| |
| 61. |
Rimm, E. B., Willett, W. C., Hu, F. B., Sampson, L., Colditz, G. A., Manson, J. E., et al. (1998) Folate and vitamin B6 from
diet and supplements in relation to risk of coronary heart disease among women. JAMA
279, 359–364.
|
| |
| 62. |
Barandier, C., Tanguy, S., Pucheu, S., Boucher, F., and de Leiris, J. (1999) Effect of antioxidant trace elements on the response
of cardiac tissue to oxidative stress. Ann. N. Y. Acad. Sci.
874, 138–155.
|
| |
| 63. |
de Lorgeril, M., Salen, P., Accominotti, M., Cadau, M., Steghens, J. P., Boucher, F., et al. (2001) Dietary and blood antioxidants
in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. Eur. J. Heart. Failure
3, 661–669.
|
| |
| 64. |
Munzel, T. and Keaney, J. F. Jr. (2001) Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation
104, 1571–1574.
|
| |
| 65. |
Tamba, M. and Torreggiani, A. (2000) Free radical scavenging and copper chelation: a potentially beneficial action of captopril.
Free Rad. Res.
32, 199–211.
|
| |
| 66. |
Feuerstein, G., Yue, T. L., Ma, X., and Ruffolo, R. R. (1998) Novel mechanisms in the treatment of heart failure: inhibition
of oxygen radicals and apoptosis by carvedilol. Prog. Cardiovasc. Dis.
41, S17–24.
|
| |
| 67. |
Roth, E. and Torok, B. (1991) Effect of the ultrashort-acting beta-blocker Brevibloc on free-radical-mediated injuries during
the early reperfusion state. Basic Res. Cardiol.
86, 422–433.
|
| |
| 68. |
Paroczai, M., Roth, E., Matos, G., Temes, G., Lantos, J., and Karpati, E. (1996) Effects of bisaramil on coronary-occlusion-reperfusion
injury and free-radical-induced reactions. Pharmacol. Res.
33, 327–336.
|
| |
| 69. |
Roth, E., Matos, G., Guarnieri, C., Papp, B., and Varga, J. (1995) Influence of the beta-blocker therapy on neutrophil superoxide
generation and platelet aggregation in experimental myocardial ischemia and reflow. Acta Physiol. Hung.
83, 163–170.
|
| |
| 70. |
Bhat, V. B. and Madyastha, K. M. (2001) Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs
pentoxifylline and lisofylline. Biochem. Biophys. Res. Commun.
288, 1212–1217.
|
| |
| 71. |
Javadov, S. A., Lim, K. H., Kerr, P. M., Suleiman, M. S., Angelini, G. D., and Halestrap, A. P. (2000) Protection of hearts
from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc. Res.
45, 360–369.
|
| |
| 72. |
Ferreira, R., Burgos, M., Llesuy, S., Molteni, L., Milei, J., Flecha, B. G., et al. (1989) Reduction of reperfusion injury
with mannitol cardioplegia. Ann. Thorac. Surg.
48, 77–83.
|
| |
| 73. |
Xu, J., Chang, Y., Ouyang, B., Lu, Z., and Li, L. (1998) Influence of isoflurane and sevoflurane on metabolism of oxygen free
radicals in cardiac valve replacement (abstract). Hunan. Yi. Ke. Da. Xue. Bao.
23, 489–491.
|
| |
| 74. |
Kelly, G. S. (1998) Clinical applications of N-acetylcysteine. Altern. Med. Rev.
3, 114–127.
|
| |
| 75. |
Marchetti, G., Lodola, E., Licciardello, L., and Colombo, A. (1999) Use of N-acetylcysteine in the management of coronary
artery diseases. Cardiologia
44, 633–637.
|
| |
| 76. |
Andrews, N. P., Prasad, A., and Quyyumi, A. A. (2001) N-acetylcysteine improves coronary and peripheral vascular function.
J. Am. Coll. Cardiol.
37, 117–123.
|
| |
| 77. |
Dage, R. C., Anderson, B. A., Mao, S. J., and Koerner, J. E. (1991) Probucol reduces myocardial dysfunction during reperfusion
after short-term ischemia in rabbit heart. J. Cardiovasc. Pharmacol.
17, 158–165.
|
| |
| 78. |
Horwitz, L. D., Fennessey, P. V., Shikes, R. H., and Kong, Y. (1994) Marked reduction in myocardial infarct size due to prolonged
infusion of an antioxidant during reperfusion. Circulation
89, 1792–1801.
|
| |
| 79. |
Miki, T., Cohen, M. V., and Downey, J. M. (1999) Failure of N-2-mercaptopropionyl glycine to reduce myocardial infarction
after 3 days of reperfusion in rabbits. Basic Res. Cardiol.
94, 180–187.
|
| |
| 80. |
Kinugawa, S., Tsutsui, H., Hayashidani, S., Ide, T., Suematsu, N., Satoh, S., et al. (2000) Treatment with dimethylthiourea
prevents left ventricular remodeling and heart failure after experimental myocardial infarction in mice: Role of oxidative
stress. Circ. Res.
87, 392–398.
|
| |
| 81. |
Hashimoto, K., Minatoguchi, S., Hashimoto, Y., Wang, N., Qiu, X., Yamashita, K., et al. (2001) role of protein kinase C, KATP
channels and DNA fragmentation in the infarct size reducing effects of the free radical scavenger T-0970. Clin. Exp. Pharmacol. Physiol.
28, 193–199.
|
| |
| 82. |
McDonald, M. C., Zacharowski, K., Bowes, J., Cuzzocrea, S., and Thiemermann, C. (1999) Tempol reduces infarct size in rodent
models of regional myocardial ischemia and reperfusion. Free Rad. Biol. Med.
27, 493–503.
|
| |
| 83. |
Headrick, J. P., Armiger, L. C., and Willis, R. J. (1990) Behaviour of energy metabolites and effect of allopurinol in the
“stunned” isovolumic rat heart. J. Mol. Cell. Cardiol.
22, 1107–1116.
|
| |
| 84. |
Khatib, S. Y., Farah, H., and El-Migdadi, F. (2001) Allopurinol enhances adenine nucleotide levels and improves myocardial
function in isolated hypoxic rat heart. Biochemistry (Mosc)
66, 328–333.
|
| |
| 85. |
Clancy, R. R., McGaurn, S. A., Goin, J. E., Hirtz, D. G., Norwood, W. I., Gaynor, J. W., et al. (2001) Allopurinol neurocardiac
protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics
108, 61–70.
|
| |
| 86. |
Soong, C. V., Young, I. S., Lightbody, J. H., Hood, J. M., Rowlands, B. J., Trimble, E. R., and BarrosD’Sa, A. A. (1994) Reduction
of free radical generation minimises lower limb swelling following femoropopliteal bypass surgery. Eur. J. Vasc. Surg.
8, 435–440.
|
| |
| 87. |
Cardillo, C., Kilcoyne, C. M., Cannon, R. O. 3rd, Quyyumi, A. A., and Panza, J. A. (1997) Xanthine oxidase inhibition with
oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension
30, 57–63.
|
| |
| 88. |
Aucamp, J., Gaspar, A., Hara, Y., and Apostolides, Z. (1997) Inhibition of xanthine oxidase by catechins from tea (Camellia sinensis). Anticancer Res.
17, 4381–4385.
|
| |
| 89. |
de Cavanagh, E. M., Inserra, F., Toblli, J., Stella, I., Fraga, C. G., and Ferder, L. (2001) Enalapril attenuates oxidative
stress in diabetic rats. Hypertension
38, 1130–1136.
|
| |
| 90. |
Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., and Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N. Engl. J. Med.
342, 145–153.
|
| |
| 91. |
Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., et al. (2001) Mechanisms underlying endothelial dysfunction
in diabetes mellitus. Circ. Res.
88, E14–22.
|
| |
| 92. |
Munzel, T., Li, H., Mollnau, H., Hink, U., Matheis, E., Hartmann, M., et al. (2000) Effects of long-term nitroglycerin treatment
on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bio-availability.
Circ. Res.
86, E7–E12.
|
| |
| 93. |
Heitzer, T., Finckh, B., Albers, S., Krohn, K., Kohlschutter, A., and Meinertz, T. (2001) Beneficial effects of alpha-lipoic
acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: Relation to parameters
of oxidative stress. Free Rad. Biol. Med.
31, 53–61.
|
| |
| 94. |
Heitzer, T., Krohn, K., Albers, S., and Meinertz, T. (2000) Tetrahydrobiopterin improves endothelium-dependent vasodilation
by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia
43, 1435–1438.
|
| |
| 95. |
Heitzer, T., Brockhoff, C., Mayer, B., Warnholtz, A., Mollnau, H., Henne, S., et al. (2000) Tetrahydrobiopterin improves endothelium-dependent
vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ. Res.
86, E36–E41.
|
| |
| 96. |
Reddy, B. R., Wynne, J., Kloner, R. A., and Przyklenk, K. (1991) Pretreatment with the iron chelator desferrioxamine fails
to provide sustained protection against myocardial ischaemia-reperfusion injury. Cardiovasc. Res.
25, 711–718.
|
| |
| 97. |
Spencer, K. T., Lindower, P. D., Buettner, G. R., and Kerber, R. E. (1998) Transition metal chelators reduce directly measured
myocardial free radical production during reperfusion. J. Cardiovasc. Pharmacol.
32, 343–348.
|
| |
| 98. |
Bolli, R., Patel, B. S., Zhu, W. X., O’Neill, P. G., Hartley, C. J., Charlat, M. L., et al. (1987) The iron chelator desferrioxamine
attenuates postischemic ventricular dysfunction. Am. J. Physiol.
253, H1372–1380.
|
| |
| 99. |
Matthews, A. J., Vercellotti, G. M., Menchaca, H. J., Bloch, P. H., Michalek, V. N., Marker, P. H., et al. (1997) Iron and
atherosclerosis: Inhibition by the iron chelator deferiprone (L1). J. Surg. Res.
73, 35–40.
|
| |
| 100. |
Porreca, E., Ucchino, S., Di Febbo, C., Di Bartolomeo, N., Angelucci, D., Napolitano, A. M., et al. (1994) Antiproliferative
effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler. Thromb.
14, 299–304.
|
| |
| 101. |
Duffy, S. J., Biegelsen, E. S., Holbrook, M., Russell, J. D., Gokce, N., Keaney, J. F. Jr., and Vita, J. A. (2001) Iron chelation
improves endothelial function in patients with coronary artery disease. Circulation
103, 2799–2804.
|
| |
| 102. |
Pepper, J. R., Mumby, S., and Gutteridge, J. M. (1994) Transient iron-overload with bleomycin-detectable iron present during
cardiopulmonary bypass surgery. Free Rad. Res.
21, 53–58.
|
| |
| 103. |
Menasche, P., Grousset, C., Gauduel, Y., Mouas, C., and Piwnica, A. (1988) A new concept of cardioplegic protection in cardiac
surgery: iron chelation. Arch. Mal. Coeur Vaiss.
81, 811–816.
|
| |
| 104. |
Menasche, P., Pasquier, C., Bellucci, S., Lorente, P., Jaillon, P., and Piwnica, A. (1988) Deferoxamine reduces neutrophil-mediated
free radical production during cardiopulmonary bypass in man. J. Thorac. Cardiovasc. Surg.
96, 582–589.
|
| |
| 105. |
Bel, A., Martinod, E., and Menasche, P. (1996) Cardioprotective effect of desferrioxamine. Acta Haematol.
95, 63–65.
|
| |
| 106. |
Stamler, A., Wang, S. Y., Aquirre, D. E., Sellke, F. W., and Johnson R. G. (1996) Effects of pentastarch-deferoxamine conjugate
on lung injury after cardiopulmonary bypass. Circulation
94, II358–II363.
|
| |
| 107. |
Black, S. C. (2000) In vivo models of myocardial ischemia and reperfusion injury. Application to drug discovery and evaluation.
J. Pharm. Toxicol. Meth.
43, 153–167.
|
| |
| 108. |
Jordan, J. E., Zhao, Z. Q., and Vinten-Johansen, J. (1999) The role of neutrophils in myocardial ischemia-reperfusion injury.
Cardiovasc. Res.
43, 860–878.
|
| |
| 109. |
Hayashi, Y., Sawa, Y., Nishimura, M., Ichikawa, H., Kagisaki, K., Ohtake, S., et al. (2000) Clinical evaluation of leukocyte-depleted
blood cardioplegia for pediatric open heart operation. Ann. Thorac. Surg.
69, 1914–1919.
|
| |
| 110. |
Riley, R. D., Sato, H., Zhao, Z. Q., Thourani, V. H., Jordan, J. E., Fernandez, A. X., et al. (2000) Recombinant human complement
C5a receptor antagonist reduces infarct size after surgical revascularization. J. Thorac. Cardiovasc. Surg.
120, 350–358.
|
| |
| 111. |
Klein, H. H., Pich, S., Bohle, R. M., Lindert, S., Nebendahl, K., Buchwald, A., et al. (1988) Antiinflammatory agent BW 755
C in ischemic reperfused porcine hearts. J. Cardiovasc. Pharmacol.
12, 338–344.
|
| |
| 112. |
Ravingerova, T., Styk, J., Tregerova, V., Pancza, D., Slezak, J., Tribulova, N., et al. (1991) Protective effect of 7-oxo-prostacyclin
on myocardial function and metabolism during postischemic reperfusion and calcium paradox. Basic Res. Cardiol.
86, 245–253.
|
| |
| 113. |
Rossoni, G., Manfredi, B., Colonna, V. D., Bernareggi, M., and Berti, F. (2001) The nitroderivative of aspirin, NCX 4016,
reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. J. Pharmacol. Exp. Ther.
297, 380–387.
|
| |
| 114. |
Bouchard, J. F. and Lamontagne, D. (1999) Mechanisms of protection afforded by cyclooxygenase inhibitors to endothelial function
against ischemic injury in rat isolated hearts. J. Cardiovasc. Pharmacol.
34, 755–763.
|
| |
| 115. |
Buchwald, A., Klein, H. H., Lindert, S., Pich, S., Nebendahl, K., Wiegand, V., and Kreuzer, H. (1989) Effect of intracoronary
superoxide dismutase on regional function in stunned myocardium. J. Cardiovasc. Pharmacol.
13, 258–264.
|
| |
| 116. |
Ambrosio, G., Becker, L. C., Hutchins, G. M., Weisman, H. F., and Weisfeldt, M. L. (1986) Reduction in experimental infarct
size by recombinant human superoxide dismutase: Insights into the pathophysiology of reperfusion injury. Circulation
74, 1424–1433.
|
| |
| 117. |
Werns, S. W., Simpson, P. J., Mickelson, J. K., Shea, M. J., Pitt, B., and Lucchesi, B. R. (1988) Sustained limitation by
superoxide dismutase of canine myocardial injury due to regional ischemia followed by reperfusion. J. Cardiovasc. Pharmacol.
11, 36–44.
|
| |
| 118. |
Ambrosio, G., Zweier, J. L., and Becker, L. C. (1998) Apoptosis is prevented by administration of superoxide dismutase in
dogs with reperfused myocardial infarction. Basic. Res. Cardiol.
93, 94–96.
|
| |
| 119. |
Naslund, U., Haggmark, S., Johansson, G., Marklund, S. L., and Reiz, S. (1990) Limitation of myocardial infarct size by superoxide
dismutase as an adjunct to reperfusion after different durations of coronary occlusion in the pig. Circ. Res.
66, 1294–1301.
|
| |
| 120. |
Naslund, U., Haggmark, S., Johansson, G., Marklund, S. L., Reiz, S., and Oberg, A. (1986) Superoxide dismutase and catalase
reduce infarct size in a porcine myocardial occlusion-reperfusion model. J. Mol. Cell. Cardiol.
18, 1077–1084.
|
| |
| 121. |
Prasad, K., Chan, W. P., and Bharadwaj, B. (1996) Superoxide dismutase and catalase in protection of cardiopulmonary bypass-induced
cardiac dysfunction and cellular injury. Can. J. Cardiol.
12, 1083–1091.
|
| |
| 122. |
Tanaka, M., Richard, V. J., Murry, C. E., Jennings, R. B., and Reimer, K. A. (1993) Superoxide dismutase plus catalase therapy
delays neither cell death nor the loss of the TTC reaction in experimental myocardial infarction in dogs. J. Mol. Cell. Cardiol.
25, 367–378.
|
| |
| 123. |
Omar, B. A. and McCord, J. M. (1990) The cardioprotective effect of Mn-superoxide dismutase is lost at high doses in the postischemic
isolated rabbit heart. Free Rad. Biol. Med.
9, 473–478.
|
| |
| 124. |
Omar, B. A., Gad, N. M., Jordan, M. C., Striplin, S. P., Russell, W. J., Downey, J. M., et al. (1990) Cardioprotection by
Cu,Zn-superoxide dismutase is lost at high doses in the reoxygenated heart. Free Rad. Biol. Med.
9, 465–471.
|
| |
| 125. |
Flaherty, J. T., Pitt, B., Gruber, J. W., Heuser, R. R., Rothbaum, D. A., Burwell, L. R., et al. (1994) Recombinant human
superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty
for acute myocardial infarction. Circulation
89, 1982–1991.
|
| |
| 126. |
Black, S. C., Schasteen, C. S., Weiss, R. H., Riley, D. P., Driscoll, E. M., and Lucchesi, B. R. (1994) Inhibition of in vivo
myocardial ischemic and reperfusion injury by a synthetic manganese-based superoxide dismutase mimetic. J. Pharm. Exp. Ther.
270, 1208–1215.
|
| |
| 127. |
Hangaishi, M., Nakajima, H., Taguchi, J., Igarashi, R., Hoshino, J., Kurokawa, K., et al. (2001) Lecithinized Cu, Zn-superoxide
dismutase limits the infarct size following ischemia-reperfusion injury in rat hearts in vivo. Biochem. Biophys. Res. Commun.
285, 1220–1225.
|
| |
| 128. |
Suzuki, K., Sawa, Y., Ichikawa, H., Kaneda, Y., and Matsuda, H. (1999) Myocardial protection with endogenous overexpression
of manganese superoxide dismutase. Ann. Thorac. Surg.
68, 1266–1271.
|
| |
| 129. |
Li, G., Chen, Y., Saari, J. T., and Kang, Y. J. (1997) Catalase-overexpressing transgenic mouse heart is resistant to ischemia-reperfusion
injury. Am. J. Physiol.
273, H1090–H1095.
|
| |
| 130. |
Zhu, H. L., Stewart, A. S., Taylor, M. D., Vijayasarathy, C., Gardner, T. J., and Sweeney, H. L. (2000) Blocking free radical
production via adenoviral gene transfer decreases cardiac ischemia-reperfusion injury. Mol. Ther.
2, 470–475.
|
| |
| 131. |
Abunasra, H. J., Smolenski, R. T., Morrison, K., Yap, J., Sheppard, M. N., O’Brien, T., et al. (2001) Efficacy of adenoviral
gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion
injury. Eur. J. Cardiothorac. Surg.
20, 153–158.
|
| |
| 132. |
Ho, Y. S., Magnenat, J. L., Gargano, M., and Cao, J. (1998) The nature of antioxidant defense mechanisms: A lesson from transgenic
studies. Environ. Health Perspect.
106(S5), 1219–28.
|
| |
| 133. |
Huang, T. T., Carlson, E. J., Raineri, I., Gillespie, A. M., Kozy, H., and Epstein, C., J. (1999) The use of transgenic and
mutant mice to study oxygen free radical metabolism. Ann. N. Y. Acad. Sci.
893, 95–112.
|
| |
| 134. |
Chen, Z., Siu, B., Ho, Y.S., Vincent, R., Chua, C. C., Hamdy, R. C., et al. (1998) Overexpression of MnSOD protects against
myocardial ischemia/reperfusion injury in transgenic mice. J. Mol. Cell. Cardiol.
30, 2281–2289.
|
| |
| 135. |
Kang, Y. J., Li, G., and Saari, J. T. (1999) Metallothionein inhibits ischemia-reperfusion injury in mouse heart. Am. J. Physiol.
276, H993–H997.
|
| |
| 136. |
Horenstein, M. S., Vander Heide, R. S., and ĽEcuyer, T. J. (2000) Molecular basis of anthracyclin-induced cardiotoxicity and
its prevention. Mol. Gen. Metab.
71, 436–444.
|
| |
| 137. |
Mohamed, H. E., El-Swefy, S. E., and Hagar, H. H. (2000) The protective effect of glutathione administration on adriamycin-induced
acute cardiac toxicity in rats. Pharmacol. Res.
42, 115–121.
|
| |
| 138. |
Stathopoulos, G. P., Malamos, N. A., Dontas, I., Deliconstantinos, G., Perrea-Kotsareli, D., and Karayannacos, P. E. (1998)
Inhibition of adriamycin cardiotoxicity by 5-fluorouracil: A potential free oxygen radical scavenger. Anticancer Res.
18, 4387–4392.
|
| |